Pipeline Insight: Non-insulin antidiabetics - Incretin mimetics - leaders in a diverse pipeline : Market Research Report

Pipeline Insight: Non-insulin antidiabetics - Incretin mimetics - leaders in a diverse pipeline

Published by: Datamonitor

Published: May. 28, 2008 - 294 Pages

ABOUT DATAMONITOR HEALTHCARE: About the cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Scope of the analysis; Datamonitor insight into the Non-insulin antidiabetics disease market; Key metrics; Datamonitor pipeline assessment summary; Related reports; Upcoming report
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS: Non-insulin antidiabetics: a diverse pipeline; Huge increase in development candidates as Western World focuses on diabetes; Market dominated by Big Pharma and single candidate companies; Current leaders - Pipeline management; Takeda; GlaxoSmithKline; Sanofi-Aventis; Others
CHAPTER 3 NON-INSULIN ANTIDIABETIC OVERVIEW - MARKET POTENTIAL: Definition of diabetes; Segmentation of diabetes; Type 1 diabetes; Type 1.5 diabetes; Type 2 diabetes; Epidemiology of diabetes; Current prevalence of type 1 and type 2 diabetes; Methodology; Epidemic rise in incidence of Type 2 diabetes; Etiology; Mechanisms of development of diabetes; Genetic or acquired causes; Risk factors; Obesity; Type 2 diabetes epidemic hand-in-hand with obesity epidemic; Race; Type 2 diabetes more prevalent in Hispanics and African Americans than in Caucasians; Family history; Type 2 diabetes in first-degree relatives is a strong prognostic indicator; Advanced age; Gender and other factors; Gestational diabetes mellitus; Unmet need in diabetes; Unmet market needs; Unmet market need 1: routine screening for the detection of type 2 diabetes mellitus; Unmet market need 2: greater patient awareness; Unmet market need 3: greater guideline awareness in physicians; Unmet clinical needs; Unmet clinical need 1: greater efficacy of non-insulin antidiabetics; Unmet clinical need 2: durability of therapy; Unmet clinical need 3: better tolerability of non-insulin antidiabetics
CHAPTER 4 R&D APPROACH: Therapy overview in type 1 and type 2 diabetes; Type 1 diabetes; Type 2 diabetes; Comparator therapies; Thiazolidinediones; Weight gain associated with TZD therapy; Actos (pioglitazone); Avandia (rosiglitazone); Sulfonylureas; Amaryl (glimepiride); Glucotrol XL (glipizide); Biguanides; Glucophage (metformin); Alpha glucosidase inhibitors; Basen (voglibose); Other classes; Classification of pipeline products; Incretin mimetics; Glucagon-like peptide-1 (GLP-1); Dipeptidyl peptidase IV (DPP-IV) inhibition; PPAR agonists; PPAR-ã agonists; Dual PPAR agonists and PPAR pan agonists; Sodium glucose co-transporter 2 (SGLT-2) inhibitors; Other classes of agents in development; Glucokinase activation; Inhibitors of glycogenolysis and gluconeogenesis; 11â-Hydroxysteroiddehydrogenase-1 inhibitors; Non-insulin antidiabetic pipeline; Incretin mimetics; DPP-IV inhibitors; GLP-1 agonists; GLP-1 fusion proteins; GPR119 agonist; Liver and muscle insulin sensitizers; PPAR system; Insulin sensitizers; Glucose excretion; Sodium dependent glucose transport-2 inhibitor; Fatty acid digestion and metabolism; Bile acid sequestrants; Carnitine palmitoyltransferase inhibitor; Farnesoid X receptor agonist; PPAR-á agonist; PPAR-ä agonist; HM74a agonist; Phase I candidates; Glucose metabolism; Fructose 1,6 bisphosphatase inhibitor; Glucagon receptor agonist; Glucokinase activators; Glucagon receptor antisense oligonucleotide; Glycogen phosphorylase inhibitor; Autoimmune dysfunction; CD-3 monoclonal antibodies; Recombinant glutamic acid decarboxylase; Heat shock protein modulators; Cell adhesion molecule modulator; Steroid hormones and the stress response; 11â-Hydroxysteroid dehydrogenase type 1 inhibitors; Glucocorticoid receptor antagonist; Biotech therapies; Alginate encapsulated pancreatic islet product; Human islet allografts; Plasmid gene therapy; Cell based therapy; Insulin vaccine; Autonomic and central nervous system; Dopamine D2 agonist; Cannabinoid (CB) -1 antagonist; Anti-inflammatory agents; Vascular cell adhesion molecule -1 (VCAM-1) gene expression inhibitor; Cyclooxygenase inhibitor; IL-1â antagonist/TNF-á antagonist/IL-6 antagonist; IL-1â antagonist; NF-êB pathway inhibitor; Insulin release stimulators; ATP dependent potassium channel inhibitor; Unknown mechanisms; Insulin signaling modulators; Protein tyrosine phosphatase -1B (PTP-1B) antisense oligonucleotide; Adenosine monophosphate (AMP) protein kinase modulator; Undisclosed insulin modulator; Combination therapies; PPAR-á agonist based therapies; PPAR-ã agonist and statin; GABA agonist and appetite suppressant; Gastrin agonist based therapies; Muscarinic acetyl choline receptor agonist and a mucolytic; Other therapeutic modes of action; Angiotensin converting enzyme inhibitors; NAD dependent deacetylase sirtuin-1 stimulator; Amyloid protein deposition inhibitor; Unknown mechanisms; Clinical trial issues in diabetes; Efficacy; Control of average blood glucose levels; Insulin; Blood markers; Weight loss; Safety and side effects; Weight gain; Cardiovascular endpoints; Comparators: add-on versus replacement therapy; Future trends; FDA guidance February 2008; Safety; Regulatory divergence - FDA versus EMEA; Combinations; Clinical endpoint selection
CHAPTER 5 NON-INSULIN ANTIDIABETIC LATE-STAGE DRUG ANALYSIS AND FORECASTS: Overview for non-insulin antidiabetics; Pipeline summary; Comparative forecasts; Definition of current comparator therapy; DPP-IV and SGLT-2 inhibitors; Saxagliptin; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; Alogliptin; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; BI-1356; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; Dapagliflozin; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; GLP-1 agonists; Byetta LAR; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; Liraglutide; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; PPAR modulators; Balaglitazone; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; MBX-102; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; Rivoglitazone; Drug overview; Forecasts to 2017; Datamonitor drug assessment summary; Marketing factors; Patient potential; Satisfaction of unmet needs; Clinical trial data; Intellectual property status; Autoimmune antibody; Teplizumab; Drug overview; Forecasts to 2017; Datamonitor drug assessment

Abstract

Introduction

Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.

Scope

Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes. A detailed clinical and commercial assessment of all key emerging therapies. Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.

Highlights

Incretin mimetics, GLP-1 agonists and DPP-IV inhibitors, are likely to be the most successful candidates in the pipeline. Pipeline incretin candidates are forecast to generate sales of $7,905m in the seven major markets in 2017 A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 137 candidates from 60 different mechanisms of action are in development Big Pharma dominate the non-insulin antidiabetic pipeline as the disease is one of the few growth areas in the cardiovascular and metabolic disease areas. Sixteen of the top twenty drug companies have a non-insulin antidiabetic pipeline and between them are developing 52% of the pipeline

Reasons to Purchase

Quantify the future drugs in the non-insulin antidiabetic market. Identify licensing opportunities based on company portfolio and market needs. Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Pipeline Insight: Non-insulin antidiabetics - Incretin mimetics - leaders in a diverse pipeline

Table of Contents

Abstract